Paul Rennert | BiotechTV

top of page

Search

Oncology expert Paul Rennert gives an update on Aleta Biotherapeutics and previews some targets at #ASCO24

Oncology expert Paul Rennert gives an update on Aleta Biotherapeutics and previews some targets at #ASCO24

Oncology expert Paul Rennert gives an update on Aleta Biotherapeutics and previews some targets at #ASCO24

Paul Rennert talks about the first four patients who have been dosed in Aleta's clinical trial, as well as previewing targets such as...

May 31, 2024

Aleta Biotherapeutics' Paul Rennert on what he sees is working, and what isn't, at #SITC23

Aleta Biotherapeutics' Paul Rennert on what he sees is working, and what isn't, at #SITC23

Aleta Biotherapeutics' Paul Rennert on what he sees is working, and what isn't, at #SITC23

Paul Rennert gives an update on Aleta, and summarizes data at #SITC23 from the IO 2.0, cytokine, TGF beta, Treg, lymphoid, and CAR-T spaces.

Nov 4, 2023

Watching cell therapy innovation at #ASCO23.

Watching cell therapy innovation at #ASCO23.

Watching cell therapy innovation at #ASCO23.

Paul Rennert of Aleta Biotherapeutics gives a rundown on the latest in cell therapies and other modalities ahead of #ASCO23.

Jun 2, 2023

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Allucent Clinical Research Organization™ is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. We’re a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.

Learn more about Allucent

bottom of page